A Safety and Efficacy Trial of a Combination of Bendamustine, Rituximab and Lenalidomide in Patients With Chronic Lymphocytic Leukemia

NCT01558167 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

22

Enrollment

OTHER

Sponsor class

Conditions

Chronic Lymphocytic Leukemia

Interventions

DRUG: Bendamustine, Rituximab, Lenalidomide

Sponsor

German CLL Study Group

Collaborators

[object Object]
[object Object]
[object Object]